You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Medications for Glomerulonephritis

Find information about funding for commonly used immunosuppressant medications for the treatment of glomerulonephritis (GN). The process for accessing each drug may vary depending on the type of drug coverage the patient has.

Drugs not covered through the Ontario Drug Benefit (ODB), Trillium Drug Program (TDP), Federal Non-Insured Health Benefits (NIHB) Program, Interim Federal Health Program (IFHP) or a manufacturer-supported program may be covered through the patient’s private insurance or paid out of pocket.

Generic and trade names for glomerulonephritis medications

GENERIC NAME 

TRADE NAMES 

Azathioprine 

Imuran® 

Cyclophosphamide 

Cytoxan®, Procytox® 

Cyclosporine 

Neoral® 

Eculizumab 

Soliris® 

Mycophenolate 

Myfortic®, CellCept® 

Prednisone 

n/a 

Rituximab 

Rituxan® 

Tacrolimus 

Prograf®, Advagraf® 

Disclaimer: The information contained herein (“Information”) is intended for informational purposes only, and no warranty as to its accuracy is provided or implied. The Information was collected from third party sources and is subject to change without notice. Cancer Care Ontario (CCO) makes no warranty that the Information is current. The Information is intended for use by healthcare professionals, subject to their clinical and/or professional judgment, to advise patients of drug funding options that may be available to them. Do not act or rely upon the Information without exercising your independent judgment or seeking the advice of a qualified professional. Anyone using the Information does so at his or her own risk. The drug funding options described herein are managed and funded by third parties, not by CCO. Please direct any inquiries to the applicable agency/entity who manages the drug funding option. CCO does not recommend or endorse the use of any drug or treatment method described herein.